Novoviah Pharmaceuticals

Novoviah Pharmaceuticals is an Australian biotechnology company focused on developing novel therapies for inflammatory and immune-mediated diseases. The company specializes in the modulation of the complement system, specifically targeting the C5a-C5aR1 axis. Its lead candidate, NOVO-202, is a potent small molecule C5a receptor antagonist designed to treat conditions such as ANCA-associated vasculitis and acute respiratory distress syndrome. By inhibiting the pro-inflammatory effects of C5a, Novoviah aims to provide more effective treatments for patients with severe inflammatory disorders. The company was founded as a spin-out from the University of Queensland, leveraging decades of research into complement biology.